EANM’05 – CME Session XIII
October 19, 2005, 10:00 – 11:30
Radiopharmaceutical chemistry of SPECT radionuclides
Moderator: G. Westera (Zuerich)
Co-Moderator: S. Mather (London)
|A. Verbruggen (Leuven):
Radiopharmaceutical chemistry of technetium and rhenium
|S. Guhlke (Bonn):
Radiopharmaceutical chemistry of iodine
|H. Maecke (Basel):
Radiopharmaceutical chemistry of trivalent metals
- List the SPECT radionuclides commonly used in Nuclear medicine and discuss the relationships between their physical properties and their clinical applications
- Describe the effects which the chemical properties of SPECT radionuclides have upon the design, preparation and biodistribution of their radiopharmaceuticals
The biodistribution of a radiopharmaceutical in Nuclear Medicine depends upon its physicochemical characteristics. To design a radiotracer which interacts with a particular target organ or tissue for a particular clinical application it is necessary to understand the influence of the chemical properties of the available radionuclides on these molecular properties.
For routine clinical application a predictable pattern of biodistribution requires high levels of purity and stability of the administered compound and these again depend on an understanding of how the targeting vector is radiolabelled.
This session will provide an introduction to aspects of the radiopharmaceutical chemistry involved in the design and preparation of SPECT radiopharmaceuticals. The speakers will describe the three main classes of radionuclides used namely (I) Technetium and rhenium, (ii) radioiodine, (iii) trivalent cationic isotopes such as indium, yttrium and gallium.
- Radiopharmaceutical Chemistry